Table 2 Risk differences of co-primary outcomes 30 days post-sotrovimab (BA.1 vs. BA.2)
Outcomes within 30 days | BA.1 (n = 70) | BA.2 (n = 15) | Risk difference, BA.2 minus BA.1 (95% CI) | P valuea |
|---|---|---|---|---|
Hospitalization due to COVID-19 | 8 (11.4%) | 1 (6.7%) | − 4.7% (− 17.9 to 16.4%) | > 0.9999 |
All-cause ICU admission | 3 (4.3%) | 0 (0%) | − 4.3% (− 12.0 to 12.7%) | > 0.9999 |
All-cause mortality | 4 (5.7%) | 0 (0%) | − 5.7% (− 13.7 to 11.6%) | > 0.9999 |